|Bid||0.00 x 1200|
|Ask||0.00 x 900|
|Day's range||39.05 - 41.73|
|52-week range||27.65 - 133.82|
|Beta (5Y monthly)||0.66|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
It's a bit early for investors to jump the ship regarding Guardant because the biotech stock still has plenty of good long-term prospects. The test will compete with the Galleri blood-based cancer screening by the Grail unit of Illumina and a the Cologuard fecal screening by Exact Sciences. Investors are also watching the outcome of a lawsuit, filed in March by Illumina, that claims that Guardant and two of its founders -- former employees of Illumina -- used Illumina's propriety information to help them launch Guardant.
The recent price decline of 49% in Guardant Health, Inc.'s ( NASDAQ:GH ) stock may have disappointed insiders who...
Shares of Guardant Health (NASDAQ: GH) were trading 23.4% lower as of 11:51 a.m. ET on Friday. The steep decline came after the company announced its first-quarter results following the market close on Thursday. This result was in line with Wall Street estimates.